Compugen Ltd. Corporation

Rotem Sorek

Zurit Levine

Amir Toporik

Sarah Rachel Pollock

Dvir Dahary

Osnat Sella-Tavor

Pinchas Akiva

Shirley Sameah-Greenwald

Amit Novik

Michal Ayalon-Soffer

Ronen Shemesh

Alexander Diber

Gad S Cojocaru

Shira Walach

Maxim Shklar

Yossi Cohen

Guy Kol

Naomi Keren

Sergey Nemzer

Lily Bazak

Michal Avalon-Soffer

Zipi Shaqed

Ariel Farkash

Novel markers for ovarian cancer that are both sensitive and accurate. These markers are overexpressed and/or differentially expressed in ovarian cancer specifically, as opposed to normal ovarian tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis, in ovarian cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between ovarian cancer and non-cancerous states.

Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer

Novel splice variant nucleic acid sequences. The novel splice variants and their nucleic acid sequences according to the present invention may optionally be used for diagnosis of a variant-detectable disease as described herein.

Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis

Novel markers for lung cancer that are both sensitive and accurate. These markers are overexpressed in lung cancer specifically, as opposed to normal lung tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of lung cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between lung cancer and non-cancerous states.

Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer

Novel markers for breast cancer that are both sensitive and accurate. These markers are overexpressed in breast cancer specifically, as opposed to normal breast tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of breast cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between breast cancer and non-cancerous states.

Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of breast cancer

Novel markers for prostate cancer that are both sensitive and accurate. Furthermore, these markers are able to distinguish between prostate cancer and benign prostate hyperplasia ('BPH'). These markers are overexpressed in prostate cancer specifically, as opposed to normal prostate tissue and/or BPH. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of prostate cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between prostate cancer and non-cancerous states.

Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer

Growing community of inventors

Rechovot, Israel

Rotem Sorek